Interpace Biosciences Company Description
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States.
It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules.
The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier; and RespriDx, a genomic test that enables physicians to differentiate metastatic or recurrent lung cancer.
It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals.
The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019.
Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
| Country | United States |
| Founded | 1986 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 111 |
| CEO | Thomas Burnell |
Contact Details
Address: Waterview Plaza Parsippany, Delaware 07054 United States | |
| Phone | 855 776 6419 |
| Website | interpace.com |
Stock Details
| Ticker Symbol | IDXG |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US46062X3035 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas W. Burnell Ph.D. | President, Chief Executive Officer and Chairman |
| Christopher McCarthy | Chief Financial Officer and Chief Operating Officer |
| Dr. Sydney D. Finkelstein M.D. | Chief Scientific Officer |
| Dr. Nicole Massoll M.D. | Chief Medical Officer |
| Patrick Kane | Vice President and Corporate Controller |